Holen Sie sich die Stockscreener-App
0.739
5.00%
0.0352
Schlusskurs vom Vortag:
$0.7038
Offen:
$0.74
24-Stunden-Volumen:
76,833
Relative Volume:
0.65
Marktkapitalisierung:
$11.82M
Einnahmen:
$19.91M
Nettoeinkommen (Verlust:
$-127.11M
KGV:
-0.0877
EPS:
-8.428
Netto-Cashflow:
$-132.44M
1W Leistung:
+2.50%
1M Leistung:
-16.79%
6M Leistung:
-78.76%
1J Leistung:
-85.22%
1-Tages-Spanne:
$0.7001
$0.7549
1-Wochen-Bereich:
$0.7001
$0.758
52-Wochen-Spanne:
$0.52
$8.95
Affimed N V Stock (AFMD) Company Profile
Vergleichen Sie AFMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.739 | 11.82M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-10-10 | Herabstufung | Stifel | Buy → Hold |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-10-21 | Eingeleitet | Truist | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2018-08-28 | Hochstufung | Jefferies | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2016-08-12 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | Eingeleitet | Laidlaw | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-09-09 | Eingeleitet | Jefferies | Hold |
| 2015-08-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-06-22 | Bestätigt | Jefferies | Buy |
Alle ansehen
Affimed N V Aktie (AFMD) Neueste Nachrichten
Affimed faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Affimed Faces Nasdaq Delisting Risk Due to Share Price - TipRanks
Affimed faces Nasdaq delisting over share price rule - Investing.com Australia
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - MSN
Affimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock News - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Over Share Price - GuruFocus
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | AFMD Stock News - GuruFocus
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Nasdaq
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Affimed Gets 180-Day Nasdaq Grace Period After Stock Falls Below $1, Extension Possible - Stock Titan
Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com - Defense World
Affimed N.V. Receives EUR 2.4 Million Research Grant from German Government to Fund Trispecific Abs - marketscreener.com
Affimed (NASDAQ:AFMD) Now Covered by Analysts at StockNews.com - Defense World
Affimed (NASDAQ:AFMD) Receives $13.50 Average Target Price from Analysts - Defense World
Short Interest in Affimed (NASDAQ:AFMD) Declines By 14.9% - Defense World
Affimed Announces Acceptance of AFM24 Abstract on Dose - GlobeNewswire
Major Cancer Conference to Showcase New AFM24 Drug Optimization Results for Lung Cancer Treatment - Stock Titan
Affimed (AFMD) to Release Earnings on Thursday - Defense World
Affimed at Leerink’s Conference: Clinical and Strategic Insights - Investing.com
Affimed at Leerink’s Conference: Clinical and Strategic Insights By Investing.com - Investing.com UK
Affimed N.V. to Host Earnings Call - ACCESS Newswire
Can Affimed's CEO Presentation Signal New Oncology Breakthroughs? Conference Watch - StockTitan
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Affimed Announces Proposed Public Offering Of Common Stock - Reuters
Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3% - Defense World
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Yahoo Finance
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - Yahoo Finance
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
Finanzdaten der Affimed N V-Aktie (AFMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):